Intel, AMD team up to confront rising challenge from Arm
Supreme Court divided in case of a trucker fired after taking CBD elixir
Trump emphasizes hypermasculinity as he and Harris pursue male voters
US warns Israel to boost humanitarian aid into Gaza or risk weapons funding
UN says deadly Israeli strike in northern Lebanon should be investigated
Countries that have cashed in on their top-level domain names
Pandas arrive in Washington DC
Logano gets back into playoffs following Bowman disqualification and has sights set on 3rd Cup title
Phillies sign manager Rob Thomson to 1-year extension after three straight trips to playoffs
Egypt's long-delayed mega-museum will open some of its main galleries, a trial run for full opening
By Blake Brittain
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages.
A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims. A GSK spokesperson said the drugmaker is "willing to license these patents on commercially reasonable terms and to ensure continued patient access."
The lawsuits add to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including one brought by Moderna against Pfizer in 2022.
Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of its and BioNTech's vaccine Comirnaty. Sales of both vaccines declined significantly last year from 2022.
GSK said in the new litigation that its patents cover mRNA technology pioneered in 2008 that provides "the foundation for Moderna's mRNA vaccine portfolio." GSK said it bought the rights to the inventions when it acquired part of Novartis' vaccine business in 2015.
(Reporting by Blake BrittainEditing by David Bario and Will Dunham)
